A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Oral Administration of HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects
Latest Information Update: 30 Jul 2024
At a glance
- Drugs HDM 1002 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Hangzhou Zhongmei Huadong Pharmaceutical
Most Recent Events
- 30 Jul 2024 New trial record